The growing popularity of aesthetic procedures is creating new opportunities for cosmetic products designed to support the skin before, during and after treatment. At the same time, it is creating a new challenge for brands: how can these products be evaluated in a clinically relevant and credible way?
Post-treatment skin is a particularly interesting field because it cannot be understood as a single, uniform condition. Depending on the procedure, the skin may experience temporary barrier disruption, increased transepidermal water loss, dehydration, erythema, inflammation, discomfort or, in some cases, later pigmentary changes.
More importantly, these responses do not always evolve at the same speed.
This means that evaluating cosmetics in this context requires a broader understanding of the skin recovery process and of the different needs that may arise throughout it.
Beyond traditional aftercare
Historically, post-procedure skincare focused mainly on supporting recovery after a controlled skin injury. The objective was to help restore skin condition, improve comfort and minimise unwanted effects during healing.
Today, the concept is expanding.
The industry is increasingly moving towards a peri-procedural skincare model, in which cosmetic products can play a role throughout the complete aesthetic treatment journey:
PREPARE → TREAT → RECOVER → OPTIMISE → MAINTAIN
This opens the door to a wider range of products and claims.
A cosmetic may be designed to prepare the skin before a procedure, provide comfort immediately afterwards, support barrier recovery, reduce visible signs associated with treatment or help maintain the final cosmetic result over time.
But the opportunity goes beyond tolerance and recovery.
Cosmetic products may also be evaluated for their ability to complement, enhance or prolong the visible benefits of an aesthetic procedure. For example, a clinical study may investigate whether combining a procedure with a specific cosmetic regimen leads to greater improvements in skin texture, radiance, pigmentation, wrinkles, firmness or hydration than the procedure alone.
In this context, the cosmetic product becomes part of the overall treatment strategy rather than simply an aftercare solution.
For brands, this also means that product development and clinical validation need to be considered together from an early stage.
Translating product positioning into clinical evidence
This is where a specialised cosmetic CRO can play an important role.
Testing a product intended for use around aesthetic procedures is not simply a matter of applying it after treatment and comparing before-and-after results.
The clinical approach should take into account the type of procedure, the expected skin response, the intended use of the product and the claims that the brand wants to support.
Different procedures may generate very different levels and types of skin response. Microneedling, chemical peels, laser treatments or other aesthetic techniques cannot necessarily be approached in the same way.
Zurko can help translate the product positioning into an appropriate clinical strategy, whether the objective is to demonstrate improved tolerance and recovery, reduced visible downtime, enhanced cosmetic efficacy or an added benefit when the product is combined with an aesthetic procedure.
The aim is to generate evidence that is not only statistically measurable, but also meaningful for the intended product benefit.
A multidimensional view of recovery and efficacy
The evaluation of peri-procedural skincare can therefore involve several overlapping dimensions.
Barrier function, hydration, inflammatory signs, visible appearance, patient comfort and pigmentation may all be relevant depending on the product and procedure. At the same time, efficacy endpoints related to the intended aesthetic benefit may also be included, such as wrinkles, skin texture, firmness, radiance or pigmentation.
For this reason, clinical evaluation often benefits from combining different types of evidence: instrumental measurements, standardised imaging, clinical grading and participant-reported outcomes.
This multidimensional approach provides a more complete picture of how the skin evolves, how the cosmetic contributes to recovery and whether it adds measurable value to the aesthetic procedure itself.
Population characteristics are also important. Skin type, sensitivity and phototype can influence recovery and the relevance of certain outcomes, particularly when pigmentary alterations are a concern.
Building better evidence for an evolving category
Peri-procedural skincare is developing rapidly, but standardised approaches to cosmetic testing in this area are still evolving.
A well-designed clinical strategy can help define realistic claims, identify the most appropriate procedure model and generate robust evidence to support product communication.
The real value lies in connecting product concept, aesthetic procedure, skin biology and clinical evidence — whether the objective is to support recovery, improve tolerance, enhance efficacy or demonstrate the added value of combining a cosmetic product with an aesthetic treatment.
